Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the pivotal Phase 3 clinical trial, the ISO-CC-007 study, for the treatment of first-line (initial) metastatic colorectal cancer (mCRC).Anders Rabbe, chief executive officer of Isofol, said, "We look forward to bringing arfolitixorin to all patients in need of an improved therapy for metastatic colorectal cancer, a devastating disease with minor therapeutic advancements in the first line treatment over the past 15 years." Following completion of the Special